Gapping up
In reaction to earnings/guidance:
- SHOP +17.2%, FROG +12.9%, SEDG +11%, LMND +10.7%, W +10.3%, PCOR +9.8%, LNTH +9.1%, SHAK +7.9%, UDMY +7.7%, QRVO +7.4%, RSI +6.6%, HUBS +6.5%, INFN +5.9%, BALL +5.8%, CPE +5.6% (also to acquire Core Delaware Basin assets and Exit Eagle Ford), DDOG +5.5%, CFLT +5.2%, PGRE +5%, BPMC +4.8%, HST +4.5%, CTSH +4.4% (also increases dividend), EQNR +4.3%, ZG +4.2%, TIXT +4.2%, OCSL +3.9%, MELI +3.8%, RACE +3.8%, NE +3.4%, CSGS +3.4%, APG +3.4%, OPK +3.3%, AMED +3.3% (also to be acquired by OPCH), NFE +3.3%, OLED +3.2% (also acquires Phosphorescent OLED Emitter IP assets of Merck), AUPH +3.2%, BRKR +3.2%, CODI +3%, QGEN +3%, VNT +3%, OWL +2.9%, KLIC +2.8%, PH +2.7%, VMEO +2.5%, CTVA +2.2%, NGVT +2.2%, NSTG +2.2%, NSTG +2.2%, DINO +2.1%, COMM +2.1%, DFH +2.1%, PLMR +2%, RGNX +2%, SRI +2%, SUM +2%, AEIS +2%, WRK +2%, CWEN +2%, PLTK +1.8%, RGLD +1.7%, RGLD +1.7%, HCC +1.6%, SHEL +1.6%, GOLF +1.6%, ACLS +1.5%, FOUR +1.4%, FATE +1.3%, ALL +1.3%, AG +1.3%, FUN +1.2%, MKSI +1.1%, AVT +1.1%, BUD +1.1%, TFX +1.1%, APA +1%, FLT +1%, SBH +1%
Other news:
- ARNC +28.2% (to be acquired by funds managed by Apollo Global Management (APO) at $30/share)
- OPTN +5.1% (FDA accepted for review its supplemental new drug application requesting approval of XHANCE as a treatment for chronic rhinosinusitis)
- AMED +3.3% (OPCH to acquire AMED in all-stock deal)
- BTBT +2.4% (reports April production)
- GFI +2.4% (Q1 operations) IMGN +2.2% ($200 mln stock offering)
- TD +2.1% (Toronto-Dominion Bank and First Horizon (FHN) agree to terminate their previously announced merger; TD to make a $200 mln payment to FHN)
- LEV +1.8% (launches the Lion5 medium-duty all-electric truck)
- NOVA +1.7% (teaming up with Amica Insurance to expand services)
- PAC +1.4% (reports April traffic)
- TTMI +1.4% (authorizes new $100 mln share repurchase program)
Analyst comments:
- WEAV +3.3% (upgraded to Outperform from Mkt Perform at Raymond James)
- CX +1.7% (upgraded to Buy from Neutral at Goldman)
- VRSK +1.6% (upgraded to Buy from Underperform at BofA Securities)
- NBIX +1.1% (upgraded to Buy from Neutral at Guggenheim)